Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab

License For Prolia And Xgeva Rivals Follows Ustekinumab Deal With Bio-Thera

Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.

Building A Brick Wall, Bricklayers
The next piece has fallen into place for Hikma’s US biosimilars business • Source: Alamy

Hikma has revealed the next piece that has been put in place as it seeks to build up a US biosimilars business, striking a licensing deal with Gedeon Richter that will allow Hikma to market exclusively the firm’s biosimilar rivals to the denosumab-based brands Prolia and Xgeva in the US.

Gedeon Richter’s proposed biosimilars – which will be used to treat osteoporosis and fractures due to bone metastasis respectively –...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business